313 related articles for article (PubMed ID: 2811008)
21. Nontuberculous mycobacterial infection of the lung in a chest hospital in Thailand.
Wongwatana S; Sriyabhaya N
J Med Assoc Thai; 1992 Jan; 75(1):1-10. PubMed ID: 1602257
[TBL] [Abstract][Full Text] [Related]
22. [A supplement study on the in vitro activity of sulfadimethoxine on Mycobacterium avium complex--combined effect with other antituberculosis drugs].
Tsukamura M
Kekkaku; 1989 Jun; 64(6):379-86. PubMed ID: 2507819
[TBL] [Abstract][Full Text] [Related]
23. [Pulmonary infection caused by Mycobacterium szulgai: a case report].
Ikeue T; Watanabe S; Sugita T; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N
Kekkaku; 2002 May; 77(5):427-31. PubMed ID: 12073621
[TBL] [Abstract][Full Text] [Related]
24. [Clinical analysis of 41 cases of pulmonary atypical mycobacteriosis].
Xia XX
Zhonghua Jie He He Hu Xi Za Zhi; 1992 Aug; 15(4):200-1, 253. PubMed ID: 1307510
[TBL] [Abstract][Full Text] [Related]
25. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait.
Ahmad S; Jaber AA; Mokaddas E
Tuberculosis (Edinb); 2007 Mar; 87(2):123-9. PubMed ID: 17289435
[TBL] [Abstract][Full Text] [Related]
26. [Analysis on the current situation of Mycobacteria other than tuberculosis during 1994-2003 in the old city area of Guangzhou].
Liu ZH; Luo CM; Cai XS
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Jun; 26(6):424-7. PubMed ID: 16185454
[TBL] [Abstract][Full Text] [Related]
27. Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance.
Kang-Birken SL; Prichard JG
Pharmacotherapy; 2006 Nov; 26(11):1646-9. PubMed ID: 17064210
[TBL] [Abstract][Full Text] [Related]
28. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
Banks J; Jenkins PA
Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
[TBL] [Abstract][Full Text] [Related]
29. Combined vs. single-drug studies of susceptibilities of Mycobacterium kansasii to isoniazid, streptomycin, and ethambutol.
Tsang AY; Bentz RR; Schork MA; Sodeman TM
Am J Clin Pathol; 1978 Nov; 70(5):816-20. PubMed ID: 717288
[TBL] [Abstract][Full Text] [Related]
30. [A case report of pulmonary Mycobacterium kansasii infection found regular medical examination in our medical college of nursing].
Inatomi K
Kekkaku; 2000 Nov; 75(11):661-4. PubMed ID: 11140089
[TBL] [Abstract][Full Text] [Related]
31. Photochromogenic and scotochromogenic mycobacteria: their clinical significance.
Gimpl F
Acta Microbiol Acad Sci Hung; 1979; 26(3):185-92. PubMed ID: 543456
[TBL] [Abstract][Full Text] [Related]
32. [A lupus-vulgaris like atypical mycobacteriosis caused by Mycobacterium xenopi (lupus xenopi)].
Kiehl P; Eicher U; Vakilzadeh F
Hautarzt; 1992 Sep; 43(9):569-75. PubMed ID: 1399603
[TBL] [Abstract][Full Text] [Related]
33. [Identification of atypical mycobacteria isolated from clinical specimens by line probe assay (LIPA)].
Biçmen C; Coşkun M; Gündüz AT; Senol G; Cirak AK; Tibet G
Mikrobiyol Bul; 2007 Oct; 41(4):503-10. PubMed ID: 18173068
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
[TBL] [Abstract][Full Text] [Related]
35. Multifocal osteomyelitis due to Mycobacterium szulgai in a patient with chronic lymphocytic leukemia.
Meyer JJ; Gelman SS
J Infect; 2008 Feb; 56(2):151-4. PubMed ID: 18199481
[TBL] [Abstract][Full Text] [Related]
36. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
[TBL] [Abstract][Full Text] [Related]
37. [Multicenter evaluation of a newly developed microdilution test, brothMIC NTM to determine minimum inhibitory concentrations of antimicrobial agents for nontuberculous mycobacteria].
Yamane N; Onaga S; Saitoh H; Toyoshima S; Shimojima M; Kawahara S; Takashima T; Yamashita T
Rinsho Byori; 2002 Apr; 50(4):381-91. PubMed ID: 12014018
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
Rastogi N; Goh KS; Guillou N; Labrousse V
Zentralbl Bakteriol; 1992 Dec; 277(4):474-84. PubMed ID: 1303690
[TBL] [Abstract][Full Text] [Related]
39. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
40. Epidemiology of disease caused by nontuberculous mycobacteria.
Horsburgh CR
Semin Respir Infect; 1996 Dec; 11(4):244-51. PubMed ID: 8976578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
